Fig. 2.

Deletion of myeloid cell COX-2 reduces tumorigenesis in neu^mmtv oncogene-driven spontaneous and orthotopic tumors. (A) Tumor onset was delayed (n = 20), (B) tumor multiplicity reduced (n = 19–20) and (C) tumors were smaller (n = 13–17) in myeloid-COX-2 KO mice transgenic for neu^mmtv (myeloid-COX-2 KO^neu) compared with WT^neu mice. (D) Myeloid-COX-2 KO^neu tumors were slower to reach a volume of 0.25cm³ compared with WT^neu mice (n = 18–19). (E) SMF mammary tumor cells grew significantly smaller tumors in myeloid-COX-2 KO recipient mice, compared with WT (n = 17–20). (F) NAF mammary tumor cells, stably expressing luciferase, were evident earlier in WT, compared with myeloid-COX-2 KO, recipient mice and were sustained over a 6-week period. (B–E) Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared with WT.